CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.2, pp.125-131, 2021 (SCI-Expanded)
This prospective study assessed the prevalence of pulmonary hypertension (PHT) related to chronic myeloproliferative neoplasms (CMPNs) and evaluated the impact of PHT on survival during long-term follow-up. In a large group of BCR-ABL1-negative CMPN patients, there was a low prevalence of PHT. The impact of PHT on survival was negligible.